Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Larimar Therapeutics, Inc. (LRMR : NSDQ)

• Company Description    Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa. Number of Employees: 65

• Price / Volume Information    Yesterday's Closing Price: $3.48 Daily Weekly Monthly 20 Day Moving Average: 1,072,120 shares Shares Outstanding: 64.03 (millions) Market Capitalization: $222.82 (millions) Beta: 0.86 52 Week High: $11.20 52 Week Low: $1.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.59% 15.11% 12 Week 82.20% 53.25% Year To Date -10.08% -15.79%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL THREE BALA PLAZA EAST. SUITE 506 - BALA CYNWYD,PA 19004 USA ph: 844-511-9056 fax: - investors@larimartx.com https://larimartx.com

• General Corporate Information    Officers Carole S. Ben-Maimon - President and Chief Executive Officer Joseph Truitt - Chairman Michael Celano - Chief Financial Officer Thomas E. Hamilton - Director Jonathan Leff - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 517125100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 64.03 Most Recent Split Date: 5.00 (0.08:1) Beta: 0.86 Market Capitalization: $222.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.89 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -70.37% vs. Previous Quarter: -2.22% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -52.48 12/31/24 - -39.68 ROA 06/30/25 - - 03/31/25 - -46.08 12/31/24 - -35.64 Current Ratio 06/30/25 - - 03/31/25 - 7.48 12/31/24 - 8.02 Quick Ratio 06/30/25 - - 03/31/25 - 7.48 12/31/24 - 8.02 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.25 12/31/24 - 2.69 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©